CALR
NM_004343.4:p.L367_A382delFs
Associated Papers
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
A rare CALR variant mutation and efficient peginterferon alfa-2a response in a patient with essential thrombocythemia.
Ciftciler R et al.
Cancer Genetics, 2023
Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms.
Kim HY et al.
Diagnostics (basel, Switzerland), 2022
Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
Maddali M et al.
Hematology/oncology and Stem Cell Therapy, 2022
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice.
Minakawa K et al.
Journal of Hematology & Oncology, 2021
Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2019
Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Lewandowski K et al.
International Journal of Laboratory Hematology, 2018
A novel molecular assay using hybridisation probes and melt curve analysis for CALR exon 9 mutation detection in myeloproliferative neoplasms.
Keaney T et al.
Journal of Clinical Pathology, 2017
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
Usseglio F et al.
The Journal of Molecular Diagnostics : Jmd, 2017
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG et al.
Oncotarget, 2016
Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2016
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
Palandri F et al.
Leukemia, 2015
Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring.
Chi J et al.
Annals of Hematology, 2015
Calreticulin mutations and long-term survival in essential thrombocythemia.
Tefferi A et al.
Leukemia, 2014
Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC et al.
Annals of Hematology, 2014
Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment.
Fu R et al.
Leukemia, 2014
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H et al.
Haematologica, 2014
Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T et al.
The New England Journal of Medicine, 2013